stammzellen
Category: All News

Company logo of PELOBIOTECH GmbH
PELOBIOTECH GmbH

PELOBiotech und XCell Therapeutics präsentieren CellCorTM Linie

Als einer der weltweit führenden Anbieter tierischer und humaner Zellen & Medien präsentiert das Unternehmen PELOBiotech, München, die CellCorTM Linie. Diese, seit knapp einem Jahr in Europa eingeführte, chemisch definierte Medium-Linie der koreanischen Xcell Therapeutics, eignet sich hervorragend für mesenchymale Stammzellen (MSCs) und ist als chemisch definiertes MSC-Medium CellCorTM CD erhältlich. Fragen? Dann treffen Sie uns auf der #ISEV 2022 in Lyon, Frankreich vom 25-29.5.22.

read more on pelobiotech.com

Pharmaceutics
pelo_logo_transparent.png
The publisher indicated in each case (see company info by clicking on image/title or company info in the right-hand column) is solely responsible for the stories above, the event or job offer shown and for the image and audio material displayed. As a rule, the publisher is also the author of the texts and the attached image, audio and information material. The use of information published here is generally free of charge for personal information and editorial processing. Please clarify any copyright issues with the stated publisher before further use. In case of publication, please send a specimen copy to service@pressebox.de.
Important note:

Systematic data storage as well as the use of even parts of this database are only permitted with the written consent of unn | UNITED NEWS NETWORK GmbH.

unn | UNITED NEWS NETWORK GmbH 2002–2024, All rights reserved

The publisher indicated in each case (see company info by clicking on image/title or company info in the right-hand column) is solely responsible for the stories above, the event or job offer shown and for the image and audio material displayed. As a rule, the publisher is also the author of the texts and the attached image, audio and information material. The use of information published here is generally free of charge for personal information and editorial processing. Please clarify any copyright issues with the stated publisher before further use. In case of publication, please send a specimen copy to service@pressebox.de.